Premium
Monocyte/macrophage differentiation in early multiple sclerosis lesions
Author(s) -
Brück Wolfgang,
Porada Phyllis,
Poser Sigrid,
Rieckmann Peter,
Hanefeld Folker,
Kretzschmarch Hans A.,
Lassmann Hans
Publication year - 1995
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410380514
Subject(s) - macrophage , multiple sclerosis , immunocytochemistry , pathology , monocyte , myelin , medicine , cd68 , demyelinating disease , antibody , antigen , immunology , immunohistochemistry , biology , central nervous system , in vitro , biochemistry
Monocyte/macrophage differentiation was studied in biopsy samples of multiple sclerosis (MS) lesions obtained in the early course of the disease. Macrophages were identified by immunocytochemistry using a panel of antibodies recognizing different macrophage‐activation antigens. The number of cells stained with each antibody was related to the demyelinating activity of the lesions as detected by the presence of myelin degradation products. The pan‐macrophage Marchker Ki‐M1P revealed the highest numbers of macrophages in early and late active lesions. Lower numbers were encountered in inactive, demyelinated, or remyelinated lesions. The acute stage inflammatory macrophage Marchkers MRP14 and 27E10 were expressed in either only early active (MRP14) or early and late active (27E10) lesions, thus allowing the identification of actively demyelinating lesions. The chronic stage inflammatory macrophage Marchker 25F9, in contrast, showed increasing expression with decreasing lesional activity. These findings indicate a differentiated pattern of macrophage activation in MS lesions and allow the staging of demyelinating lesions in routinely fixed and paraffin‐embedded tissue.